Share Twitter LinkedIn Facebook Email Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .
FDA Approves Opdivo / Nivolumab Plus Yervoy / Ipilimumab for MSI-H/dMMR Colorectal Cancer: A Precision Oncology Milestone Colorectal 3 Mins Read
Pashtoon Kasi MD, MS – The Role of Circulating Tumor DNA (ctDNA) in Colorectal Cancer Management – ASCO GI 2025 Colorectal 4 Mins Read
FDA Approves Sotorasib / Lumakras + Panitumumab / Vectibix for KRAS G12C Mutation Extending Survival Colorectal 3 Mins Read